COLUMBIA, Md., Dec. 17 /PRNewswire-FirstCall/ -- Celsion Corporation announced today that Celsion, in partnership with the American Liver Foundation (ALF), launched a CME accredited educational webcast for physicians that features recent advances made in the treatment of hepatocellular carcinoma(HCC) and Celsion's ThermoDox(R) Phase III HEAT clinical study.
"Dr. Poon's webcast provides current information for physicians and patients, as it highlights the evolution and recent advances made in the treatment of HCC," stated Michael H. Tardugno, Celsion's President and Chief Executive Officer. "The webcast underscores the need for innovative, new therapies such as ThermoDox because despite recent improvements in treatment, five year HCC survival rates are still in the single digits. ThermoDox has demonstrated remarkable evidence of clinical utility in early stage clinical trials and holds great promise for HCC patients as there is currently no chemotherapeutic standard of care."
ThermoDox has demonstrated evidence of efficacy in a Phase I study for primary liver cancer and the FDA has granted Orphan Drug designation for this indication. For recurrent chest wall breast cancer, ThermoDox is being evaluated in a pivotal Phase I/II open-label, dose-escalating trial that is designed to measure durable local complete response at the tumor site.
For more information on Celsion, visit our website: http://www.celsion.com
Celsion Corporation
